In year 2 under new CEO, troubled Leo Pharma makes progress
Timber Pharmaceuticals Presents Late-Breaking Preliminary Results of TMB-001
LEO Unveils Late-Breaking Data for Landmark DELTA 3 Open-Label Extension Trial
LEO Pharma Presents New Long-Term Adbry® (tralokinumab-ldrm) Data
LEO Pharma to Maintain Leadership Role at AAD in 2024
LEO Pharma Delivers 10% Revenue Growth and Returns to Positive EBITDA
LEO Pharma Announces Positive Phase 3 Head-to-head Data Results from DELTA FORCE Trial Comparing Delgocitinib Cream With Alitretinoin Capsules in Adults With Severe Chronic Hand Eczema (CHE)
It’s been four years since Japan Tobacco snagged approval in its home country for its topical JAK inhibitor delgocitinib to treat atopic dermatitis.
LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals
LEO Pharma Presents Data at 2024 Winter Clinical and Maui Derm Conferences